Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03372057 · ClinicalTrials.gov registry record · Phase 2
A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Phase 2 study of Peripheral T-Cell Lymphoma, sponsored by SecuraBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
- 20
- Study locations
NCT03372057: Completed Phase 2 study of Peripheral T-Cell Lymphoma, sponsored by SecuraBio.
NCT03372057 is a Phase 2 study of Peripheral T-Cell Lymphoma that has completed, run by SecuraBio. The registered enrollment target is 156 participants, above the 102-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (53% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03372057, a Phase 2 study of Peripheral T-Cell Lymphoma, has completed, sponsored by SecuraBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with relapsed/refractory peripheral T-cell lymphoma (PTCL).
Primary Outcome
ORR was defined as the percentage of participants with CR + PR, as assessed by the investigator using the Lugano criteria, for participants receiving the optimal dose of duvelisib for at least one cycle of study therapy.
Conditions Studied
Interventions
- DRUG Duvelisib
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- University of California - Irvine - Irvine
- University of California - Los Angeles - Los Angeles
New York
- Memorial Sloan Kettering Cancer Center - New York
- University of Rochester - Rochester
- Stony Brook Cancer Center - Stony Brook
North Carolina
- Levine Cancer Institute - Charlotte
- Novant Health - Charlotte
- Duke University - Durham
Ohio
- The Ohio State University - Columbia
- Toledo Cancer Center - Toledo
Georgia
- Emory University Winship Cancer Institute - Atlanta
Illinois
- Northwestern University - Feinberg School of Medicine - Chicago
Kentucky
- Norton Cancer Institute - Louisville
Maryland
- University of Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2018-02-22 |
| Est. Completion | 2023-12-22 |
| Phase | Phase 2 |
What the finished NCT03372057 record still lists
NCT03372057 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, above the 102-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (53% higher).
The record links to 1 condition, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Duvelisib is the first listed.
NCT03372057 names 20 study sites across 13 states, led by California, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03372057 about?
NCT03372057 is a clinical study titled "A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)". This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with relapsed/refractory peripheral T-cell lymphoma (PTCL).
What is the current status of trial NCT03372057?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2018-02-22. Estimated completion is 2023-12-22.
What conditions does trial NCT03372057 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma.
What interventions are being tested in trial NCT03372057?
The interventions under investigation include: Duvelisib (DRUG).
Who is sponsoring clinical trial NCT03372057?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03372057 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03372057's enrollment target sits among peer trials
156 5th of 34 higher than 30 of 34 other Peripheral T-Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral T-Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI